Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a sustained high level of demand during the quarter, though it is expected to slowdown in the subsequent quarters. Nonetheless, the acceleration in the non-COVID-19 business – driven by new product launches and the normalisation of the market as people get vaccinated – should ensure that the FY21 targets ....
